

Librassay[®] Opens up Nonexclusive Access to Patents for Molecular Diagnostics and Personalized Medicine

Exclusive licensing practices and related legal skirmishes cry out for nonexclusive access to patents in the diagnostic field of use. [MPEG LA](#) is answering that call with [Librassay[®]](#), a web-based marketplace of nonexclusive patent rights.

“Our role is to help patent owners and users come together in an efficient fashion to hasten transactions that incentivize technology innovation and adoption by balancing reasonable access to patent rights for users with a reasonable return on technology investment for patent owners,” said Kristin Neuman, Executive Director of Librassay[®].

The nonexclusive licensing platform provided by Librassay[®] will promote the availability of molecular diagnostic testing and related kits and tools by providing a wide variety of patent rights in a single, easy, and cost-effective transaction. Librassay[®] will be launched with an on-line shopping site, where licensees can “browse aisles” for patent rights of value to their developmental and commercial products. As more and more patents join the Librassay[®] store, packages of patent rights will be offered around specific technologies and platforms. The medical community will experience greater levels of diagnostic test availability because no entity will license patents from Librassay[®] on an exclusive basis – Librassay[®] patent licenses will be nonexclusive. MPEG LA expects the widespread, nonexclusive licensing opportunities available through Librassay[®] to drive down the cost of molecular diagnostic testing, while providing patent owners with a financial return on their innovations.

More information on Librassay[®] is available at www.librassay.com, or by emailing biotech@mpegla.com.